CORRIGENDUM


Jan Lötvall a,*, Eugene R. Bleecker b, William W. Busse c, Paul M. O’Byrne d, Ashley Woodcock e, Edward M. Kerwin f, Sally Stone g, Richard Forth h, Loretta Jacques g, Eric D. Bateman i

a Krefting Research Centre, University of Gothenburg, Box 424, SE 40530 Gothenburg, Sweden
b Center for Genomics and Personalized Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
c Department of Medicine, University of Wisconsin, Madison, WI 53706, USA
d Michael G DeGroote School of Medicine, Hamilton, Ontario L8S4L8, Canada
e Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester, Manchester M23 9LT, UK
f Clinical Research Institute of Southern Oregon, Medford, OR 97504, USA
g Respiratory Medicine Development Centre, GlaxoSmithKline, London UB11 1BT, UK
h Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, NC 27713, USA
i Department of Medicine, University of Cape Town, Cape Town 7925, South Africa

The authors regret that an error occurred in Table 2 in the above-mentioned article.

The data on the fourth row of the table, labelled “Morning PEF (l/min): difference in LS mean change from baseline (95% CI) over weeks 1–24”, should read as follows:

- FF100 μg OD vs. placebo: 12.1 (4.0, 20.2)

- FP250 μg BD vs. placebo: 7.6 (−0.5, 15.7)

This amendment does not materially affect the findings or interpretations presented in the manuscript.

The authors would like to apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.rmed.2013.11.009.

* Corresponding author. Tel.: +46 31 3427282; fax: +46 31 415239.
E-mail address: jan.lotvall@gu.se (J. Lötvall).